Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.

@article{Klintmalm2007CorticosteroidfreeIW,
  title={Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.},
  author={Goran B. G. Klintmalm and William Kenneth Washburn and Steven M Rudich and Thomas G Heffron and Lewis W. Teperman and Carlos Fasola and Devin Eckhoff and George J Netto and Eliezer Katz},
  journal={Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society},
  year={2007},
  volume={13 11},
  pages={1521-31}
}
This work is a 1-yr interim analysis of a prospective, randomized, multicenter trial evaluating the effect of corticosteroid-free immunosuppression on hepatitis C virus-positive (HCV(+)) liver transplant recipients following liver transplantation (LT). Patients received tacrolimus and corticosteroids (Arm 1; n = 80); tacrolimus, corticosteroids, and mycophenolate mofetil (MMF) (Arm 2; n = 79); or daclizumab induction, tacrolimus, and MMF (Arm 3; n = 153). At 1 yr, 64.1%, 63.4%, and 69.4% of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Similar Papers

Loading similar papers…